Therapeutic Classes/RANK Ligand Inhibitor

RANK Ligand Inhibitor

5 drugs across 2 manufacturers|0 Generic,5 Brand

The RANK Ligand Inhibitor class contains 5 NDCs from 2 manufacturers (0 generic, 5 brand), at an average NADAC of $1853.55 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.

Total Drugs

5

0G / 5B

Manufacturers

2

Avg $1853.5454/unit

Avg 7d Change

0.00%

Across 0 drugs with changes

7d Activity

5 flat

of 5 total drugs

Class Price Trend

Monthly average NADAC price per unit, split by generic and brand

Manufacturer Breakdown

2 manufacturers producing drugs in this therapeutic class

Drug Portfolio

5 drugs total, 5 shown

Drug Price 7d Change
XGEVA 120 MG/1.7 ML VIAL
denosumab
$2001.5168
per ML
XGEVA 120 MG/1.7 ML VIAL
denosumab
$2001.5168
per ML
PROLIA 60 MG/ML SYRINGE
denosumab
$1863.7230
per ML
0.00%
PROLIA 60 MG/ML SYRINGE
denosumab
$1863.7230
per ML
0.00%
JUBBONTI 60 MG/ML SYRINGE
denosumab
$1537.2474
per ML
0.00%

Frequently Asked Questions

How many drugs are in the RANK Ligand Inhibitor class?

The RANK Ligand Inhibitor class contains 5 NDCs from 2 manufacturers — 0 generic and 5 brand products.

What is the average price of RANK Ligand Inhibitor drugs?

The average NADAC for the RANK Ligand Inhibitor class is $1853.5454 per unit across 5 NDCs.

Which manufacturers make RANK Ligand Inhibitor drugs?

2 manufacturers make drugs in the RANK Ligand Inhibitor class. Ranked by number of NDCs, the largest are Amgen Inc. (4), Sandoz Inc. (1).